NCT07164183 - Clinical Study to Compare Efficacy and Safety of Indinol Forto® 200 mg Capsules and Visanne 2 mg Tablets in Treatment of Endometriosis | Biotech Hunter

Enrollment

290

Participants

Timeline

Start Date

September 11, 2025

Primary Completion Date

October 31, 2026

Study Completion Date

November 30, 2026

Conditions

Endometriosis

Interventions

DRUG

Indole-3-carbinol

Indinol Forto (indolecarbinol (indole-3-carbinol)) 200 mg capsules orally twice a day during 24 weeks

DRUG

Dienogest

Visanne (dienogest) 2 mg tablets orally once a day during 24 weeks

Trial Locations (8)

NOT_YET_RECRUITING

Research Site, Kazan'

NOT_YET_RECRUITING

Research Site, Moscow

NOT_YET_RECRUITING

Research Site, Rostov-on-Don

RECRUITING

Research Site, Ryazan

NOT_YET_RECRUITING

Research Site, Saint Petersburg

RECRUITING

Research Site, Smolensk

NOT_YET_RECRUITING

Research Site, Tver'

RECRUITING

Research Site, Yaroslavl